Guy Griebel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5292755/publications.pdf

Version: 2024-02-01

141 papers	13,090 citations	23565 58 h-index	24978 109 g-index
166 all docs	166 docs citations	166 times ranked	9949 citing authors

#	Article	IF	Citations
1	Measuring normal and pathological anxiety-like behaviour in mice: a review. Behavioural Brain Research, 2001, 125, 141-149.	2.2	753
2	Drug-Dependent Requirement of Hippocampal Neurogenesis in a Model of Depression and of Antidepressant Reversal. Biological Psychiatry, 2008, 64, 293-301.	1.3	482
3	Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V _{1b} receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6370-6375.	7.1	450
4	5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research. , 1995, 65, 319-395.		438
5	Antidepressants recruit new neurons to improve stress response regulation. Molecular Psychiatry, 2011, 16, 1177-1188.	7.9	406
6	Differences in anxiety-related behaviours and in sensitivity to diazepam in inbred and outbred strains of mice. Psychopharmacology, 2000, 148, 164-170.	3.1	379
7	Mouse defensive behaviors: pharmacological and behavioral assays for anxiety and panic. Neuroscience and Biobehavioral Reviews, 2001, 25, 205-218.	6.1	379
8	Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends in Pharmacological Sciences, 2003, 24, 580-588.	8.7	374
9	50 years of hurdles and hope in anxiolytic drug discovery. Nature Reviews Drug Discovery, 2013, 12, 667-687.	46.4	334
10	Risk assessment as an evolved threat detection and analysis process. Neuroscience and Biobehavioral Reviews, 2011, 35, 991-998.	6.1	329
11	Blockade of CRF1 or V1b receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Molecular Psychiatry, 2004, 9, 278-286.	7.9	283
12	4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine Hydrochloride (SSR125543A), a Potent and Selective Corticotrophin-Releasing Factor1 Receptor Antagonist. II. Characterization in Rodent Models of Stress-Related Disorders. Journal of Pharmacology and Experimental Therapeutics, 2002, 301, 333-345.	2.5	242
13	SSR180711, a Novel Selective Î±7 Nicotinic Receptor Partial Agonist: (II) Efficacy in Experimental Models Predictive of Activity Against Cognitive Symptoms of Schizophrenia. Neuropsychopharmacology, 2007, 32, 17-34.	5.4	239
14	Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biological Psychiatry, 2005, 57, 261-267.	1.3	238
15	Nicotine-Associated Cues Maintain Nicotine-Seeking Behavior in Rats Several Weeks after Nicotine Withdrawal: Reversal by the Cannabinoid (CB1) Receptor Antagonist, Rimonabant (SR141716). Neuropsychopharmacology, 2005, 30, 145-155.	5.4	235
16	The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic. European Journal of Pharmacology, 2003, 463, 97-116.	3.5	231
17	Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries. Neuroscience and Biobehavioral Reviews, 1997, 21, 783-789.	6.1	223
18	Characterization of (2S,4R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydr carboxamide (SSR149415), a Selective and Orally Active Vasopressin V_{1b}Receptor Antagonist. Journal of Pharmacology and Experimental Therapeutics, 2002, 300, 1122-1130.	2.5	222

#	Article	IF	Citations
19	Neurochemical, Electrophysiological and Pharmacological Profiles of the Selective Inhibitor of the Glycine Transporter-1 SSR504734, a Potential New Type of Antipsychotic. Neuropsychopharmacology, 2005, 30, 1963-1985.	5.4	215
20	Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 625-631.	4.8	202
21	Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Psychopharmacology, 1998, 138, 55-66.	3.1	200
22	SSR180711, a Novel Selective Î±7 Nicotinic Receptor Partial Agonist: (1) Binding and Functional Profile. Neuropsychopharmacology, 2007, 32, 1-16.	5.4	183
23	Risk Assessment Behaviour: Evaluation of Utility in the Study of 5-HT-Related Drugs in the Rat Elevated Plus-Maze Test. Pharmacology Biochemistry and Behavior, 1997, 57, 817-827.	2.9	177
24	Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?. Nature Reviews Drug Discovery, 2012, 11, 462-478.	46.4	175
25	Corticolimbic Transcriptome Changes are State-Dependent and Region-Specific in a Rodent Model of Depression and of Antidepressant Reversal. Neuropsychopharmacology, 2009, 34, 1363-1380.	5.4	173
26	Conditioning and residual emotionality effects of predator stimuli: some reflections on stress and emotion. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 1177-1185.	4.8	169
27	Is There a Future for Neuropeptide Receptor Ligands in the Treatment of Anxiety Disorders?. , 1999, 82, 1-61.		153
28	Behavioral and neurochemical changes following predatory stress in mice. Neuropharmacology, 2001, 41, 400-408.	4.1	125
29	CB receptor antagonists for the treatment of nicotine addiction. Pharmacology Biochemistry and Behavior, 2005, 81, 387-395.	2.9	124
30	A Comparative Study of the Effects of Selective and Non-Selective 5-HT2 Receptor Subtype Antagonists in Rat and Mouse Models of Anxiety. Neuropharmacology, 1997, 36, 793-802.	4.1	122
31	Some critical determinants of the behaviour of rats in the elevated plus-maze. Behavioural Processes, 1993, 29, 37-47.	1.1	120
32	Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. Psychopharmacology, 1994, 113, 463-470.	3.1	119
33	Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology, 1995, 120, 57-66.	3.1	106
34	Evidence that the Lateral Septum is Involved in the Antidepressant-Like Effects of the Vasopressin V1b Receptor Antagonist, SSR149415. Neuropsychopharmacology, 2005, 30, 35-42.	5.4	106
35	Stimulation of the Î²3-Adrenoceptor as a Novel Treatment Strategy for Anxiety and Depressive Disorders. Neuropsychopharmacology, 2008, 33, 574-587.	5.4	102
36	Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression. European Journal of Pharmacology, 2004, 497, 49-53.	3.5	99

#	Article	IF	Citations
37	Further evidence that the mouse defense test battery is useful for screening anxiolytic and panicolytic drugs: Effects of acute and chronic treatment with alprazolam. Neuropharmacology, 1995, 34, 1625-1633.	4.1	96
38	Orphanin FQ, a novel neuropeptide with anti-stress-like activity. Brain Research, 1999, 836, 221-224.	2.2	94
39	Functional and Pharmacological Characterization of the First Specific Agonist and Antagonist for the V1b Receptor in Mammals. Stress, 2003, 6, 199-206.	1.8	92
40	Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents. Scientific Reports, 2015, 5, 7642.	3.3	91
41	4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-ami Hydrochloride (SSR125543A): A Potent and Selective Corticotrophin-Releasing Factor1Receptor Antagonist. I. Biochemical and Pharmacological Characterization. Journal of Pharmacology and Experimental Therapeutics, 2002, 301, 322-332.	2.5	87
42	Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophreniaâ˜† . Pharmacology Biochemistry and Behavior, 2008, 91, 47-58.	2.9	87
43	AVP V selective antagonist SSR149415 blocks aggressive behaviors in hamsters. Pharmacology Biochemistry and Behavior, 2005, 80, 189-194.	2.9	85
44	Non-Peptide Vasopressin V1b Receptor Antagonists as Potential Drugs for the Treatment of Stress-Related Disorders. Current Pharmaceutical Design, 2005, 11, 1549-1559.	1.9	84
45	Behavioral Effects of Acute and Chronic Fluoxetine in Wistarâ€“Kyoto Rats. Physiology and Behavior, 1999, 67, 315-320.	2.1	82
46	Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats. Psychopharmacology, 2006, 187, 237-244.	3.1	82
47	New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ (Ï‰) receptor subtypes. Psychopharmacology, 1999, 146, 205-213.	3.1	77
48	Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology, 2009, 202, 385-396.	3.1	74
49	Benzodiazepine and Serotonergic Modulation of Antipredator and Conspecific Defense. Neuroscience and Biobehavioral Reviews, 1998, 22, 597-612.	6.1	72
50	The effects of compounds varying in selectivity as 5-HT1A receptor antagonists in three rat models of anxiety. Neuropharmacology, 2000, 39, 1848-1857.	4.1	72
51	An Overview of SSR149415, a Selective Nonpeptide Vasopressin V1b Receptor Antagonist for the Treatment of Stress-Related Disorders. CNS Neuroscience & Therapeutics, 2005, 11, 53-68.	4.0	71
52	SL651498, a GABA_A Receptor Agonist with Subtypeâ€Selective Efficacy, as a Potential Treatment for Generalized Anxiety Disorder and Muscle Spasms. CNS Neuroscience & Therapeutics, 2003, 9, 3-20.	4.0	70
53	Gender bias in the preclinical psychopharmacology of anxiety: male models for (predominantly) female disorders. Journal of Psychopharmacology, 1995, 9, 79-82.	4.0	69
54	The Vasopressin V1b Receptor as a Therapeutic Target in Stress-related Disorders. CNS and Neurological Disorders, 2003, 2, 191-200.	4.3	69

#	Article	IF	Citations
55	The Vasopressin V_{1b}Receptor Antagonist SSR149415 in the Treatment of Major Depressive and Generalized Anxiety Disorders. Journal of Clinical Psychiatry, 2012, 73, 1403-1411.	2.2	67
56	Comparison of the behavioural effects of an adenosine A1/A2-receptor antagonist, CGS 15943A, and an A1-selective antagonist, DPCPX. Psychopharmacology, 1991, 103, 541-544.	3.1	65
57	The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimerâ€™s disease in rodents. Scientific Reports, 2019, 9, 18045.	3.3	62
58	Evidence that the Behaviors in the Mouse Defense Test Battery Relate to Different Emotional States: A Factor Analytic Study. Physiology and Behavior, 1996, 60, 1255-1260.	2.1	61
59	Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils. Pharmacology Biochemistry and Behavior, 2006, 83, 533-539.	2.9	61
60	Predator-elicited plight responses in Swiss-Webster Mice: An experimental model of panic attacks. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1996, 20, 185-205.	4.8	60
61	Pharmacological studies on synthetic flavonoids: comparison with diazepam. Neuropharmacology, 1999, 38, 965-977.	4.1	60
62	Behavioral profile of the 5HT1A receptor antagonist (S)-UH-301 in rodents and monkeys. Brain Research Bulletin, 1992, 29, 901-904.	3.0	59
63	Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models. Pharmacology Biochemistry and Behavior, 2008, 89, 36-45.	2.9	58
64	Genetic differences in the mouse defense test battery. Aggressive Behavior, 1997, 23, 19-31.	2.4	56
65	Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat. Pharmacology Biochemistry and Behavior, 2005, 82, 223-227.	2.9	56
66	The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents. Scientific Reports, 2018, 8, 2416.	3.3	56
67	Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamineâ€“oxidase activity and monoamine levels. Neuropharmacology, 1998, 37, 927-935.	4.1	55
68	SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats. Neuropharmacology, 2004, 46, 1121-1129.	4.1	55
69	Pro-Cognitive and Antipsychotic Efficacy of the Î±7 Nicotinic Partial Agonist SSR180711 in Pharmacological and Neurodevelopmental Latent Inhibition Models of Schizophrenia. Neuropsychopharmacology, 2009, 34, 1753-1763.	5.4	55
70	Effects of SR48968, a selective non-peptide NK 2 receptor antagonist on emotional processes in rodents. Psychopharmacology, 2001, 158, 241-251.	3.1	54
71	Behavioural profiles in the mouse defence test battery suggest anxiolytic potential of 5-HT 1A receptor antagonists. Psychopharmacology, 1999, 144, 121-130.	3.1	53
72	Acute inescapable stress exposure induces long-term sleep disturbances and avoidance behavior: A mouse model of post-traumatic stress disorder (PTSD). Behavioural Brain Research, 2011, 221, 149-154.	2.2	53

#	Article	IF	Citations
73	Optogenetics to study the circuits of fear- and depression-like behaviors: A critical analysis. Pharmacology Biochemistry and Behavior, 2014, 122, 144-157.	2.9	53
74	An Ethopharmacological Analysis of Selective Activation of 5-HT1A Receptors: The Mouse 5-HT1A Syndrome. Pharmacology Biochemistry and Behavior, 1997, 57, 897-908.	2.9	51
75	SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit. Psychopharmacology, 2005, 181, 134-144.	3.1	50
76	Confirmation of antidepressant potential of the selective Î²3 adrenoceptor agonist amibegron in an animal model of depression. Pharmacology Biochemistry and Behavior, 2008, 89, 623-626.	2.9	49
77	Disruption of the Prepulse Inhibition of the Startle Reflex in Vasopressin V1b Receptor Knockout Mice: Reversal by Antipsychotic Drugs. Neuropsychopharmacology, 2005, 30, 1996-2005.	5.4	46
78	Neuropeptides in Psychiatric Diseases: An Overview with a Particular Focus on Depression and Anxiety Disorders. CNS and Neurological Disorders - Drug Targets, 2006, 5, 135-145.	1.4	46
79	5-HT1A agonists modulate mouse antipredator defensive behavior differently from the 5-HT2A antagonist pirenperone. Pharmacology Biochemistry and Behavior, 1995, 51, 235-244.	2.9	45
80	Defensive Responses to Predator Threat in the Rat and Mouse. Current Protocols in Neuroscience, 2005, 30, Unit 8.19.	2.6	45
81	AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology, 2011, 215, 149-163.	3.1	45
82	CCK receptor antagonists in animal models of anxiety: comparison between exploration tests, conflict procedures and a model based on defensive behaviours. Behavioural Pharmacology, 1997, 8, 549-560.	1.7	44
83	The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia. Scientific Reports, 2016, 6, 35320.	3.3	43
84	Contribution of GABAAReceptor Subtypes to the Anxiolytic-Like, Motor, and Discriminative Stimulus Effects of Benzodiazepines: Studies with the Functionally Selective Ligand SL651498 [6-Fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-pyridol[3,4-b]indol-1-one]. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 1118-1125.	2.5	42
85	Cortico-limbic circuitry for conditioned nicotine-seeking behavior in rats involves endocannabinoid signaling. Psychopharmacology, 2007, 194, 161-171.	3.1	41
86	The Glycine Transporter-1 Inhibitor SSR103800 Displays a Selective and Specific Antipsychotic-like Profile in Normal and Transgenic Mice. Neuropsychopharmacology, 2010, 35, 416-427.	5.4	41
87	Comparison of the pharmacological properties of classical and novel BZ-Ï‰ receptor ligands. Behavioural Pharmacology, 1999, 10, 483-495.	1.7	40
88	SSR240600 [(R)-2-(1-{2-[4-{2-[3,5-Bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl}-4-piperidinyl)-2-methylpropanamid a Centrally Active Nonpeptide Antagonist of the Tachykinin Neurokinin 1 Receptor: II. Neurochemical and Behavioral Characterization. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 1180-1188.	2.5	40
89	Antidepressant-Like Effects of the Corticotropin-Releasing Factor 1 Receptor Antagonist, SSR125543, and the Vasopressin 1b Receptor Antagonist, SSR149415, in a DRL-72â€‰s Schedule in the Rat. Neuropsychopharmacology, 2006, 31, 2180-2187.	5.4	39
90	SAR110894, a potent histamine H3-receptor antagonist, displays procognitive effects in rodents. Pharmacology Biochemistry and Behavior, 2012, 102, 203-214.	2.9	39

#	Article	IF	Citations
91	Mice Deficient in Cryptochrome 1 (Cry1Ã¢Ë†â€™/Ã¢Ë†â€™) Exhibit Resistance to Obesity Induced by a High-Fat Diet. Frontiers in Endocrinology, 2014, 5, 49.	3.5	39
92	Behavioral effects of rolipram and structurally related compounds in mice: Behavioral sedation of cAMP phosphodiesterase inhibitors. Pharmacology Biochemistry and Behavior, 1991, 39, 321-323.	2.9	38
93	Deep brain stimulation in treatment-resistant depression in mice: Comparison with the CRF1 antagonist, SSR125543. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 40, 213-220.	4.8	38
94	Anxiolytic-like effects of a selective 5-HT1A agonist, S20244, and its enantiomers in mice. NeuroReport, 1992, 3, 84-86.	1.2	37
95	Further evidence for differences between non-selective and BZ-1 (Ï‰1) Selective, benzodiazepine receptor ligands in murine models of â€œstateâ€•and â€œtraitâ€•Anxiety. Neuropharmacology, 1996, 35, 1081-1091.	4.1	37
96	Effects of the CRF1 antagonist SSR125543A on aggressive behaviors in hamsters. Pharmacology Biochemistry and Behavior, 2004, 77, 465-469.	2.9	36
97	m-Chlorophenylpiperazine enhances neophobic and anxious behaviour in mice. NeuroReport, 1991, 2, 627.	1.2	35
98	Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery. Neuroscience and Biobehavioral Reviews, 2001, 25, 619-626.	6.1	33
99	Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents. Journal of Psychopharmacology, 1998, 12, 356-365.	4.0	32
100	Î²-CCT, a selective BZ-Ï‰1 receptor antagonist, blocks the anti-anxiety but not the amnesic action of chlordiazepoxide in mice. Behavioural Pharmacology, 2000, 11, 125-131.	1.7	32
101	Long-term impaired memory following predatory stress in mice. Physiology and Behavior, 2006, 87, 45-50.	2.1	32
102	Behavioural profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs. Psychopharmacology, 1997, 131, 180-186.	3.1	30
103	Anxiolytic and sedative effects of 5-HT1A ligands, 8-OH-DPAT and MDL 73005EF, in mice. NeuroReport, 1990, 1, 267.	1.2	28
104	Discriminative Stimulus Effects of Drugs Acting at GABAA Receptors. Pharmacology Biochemistry and Behavior, 1999, 64, 269-273.	2.9	28
105	Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases?. , 2012, 133, 116-123.		28
106	Implication of Î²3-adrenoceptors in the antidepressant-like effects of amibegron using Adrb3 knockout mice in the chronic mild stress. Behavioural Brain Research, 2010, 206, 310-312.	2.2	25
107	Serenics fluprazine (DU 27716) and eltoprazine (DU 28853) enhance neophobic and emotional behaviour in mice. Psychopharmacology, 1990, 102, 498-502.	3.1	24
108	Impaired memory following predatory stress in mice is improved by fluoxetine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004, 28, 123-128.	4.8	24

#	Article	IF	Citations
109	The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice. Pharmacology Biochemistry and Behavior, 2011, 98, 425-431.	2.9	24
110	Phencyclidine decreases tickling-induced 50-kHz ultrasound vocalizations in juvenile rats. Behavioural Pharmacology, 2013, 24, 543-551.	1.7	24
111	The CRF1 receptor antagonist SSR125543 attenuates long-term cognitive deficit induced by acute inescapable stress in mice, independently from the hypothalamic pituitary adrenal axis. Pharmacology Biochemistry and Behavior, 2012, 102, 415-422.	2.9	21
112	The CRF1 receptor antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with paroxetine and d-cycloserine. Psychopharmacology, 2013, 228, 97-107.	3.1	19
113	Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression. Pharmacology Biochemistry and Behavior, 2010, 96, 206-210.	2.9	18
114	Behavioural effects of selective A2 adenosine receptor antagonists, CGS 21197 and CGS 22706, in mice. NeuroReport, 1991, 2, 139-140.	1.2	17
115	Differences in Anxiolytic-Like Profile of Two Novel Nonbenzodiazepine BZ (Ï–) Receptor Agonists on Defensive Behaviors of Mice. Pharmacology Biochemistry and Behavior, 1999, 62, 689-694.	2.9	17
116	Further evidence for the sleep-promoting effects of 5-HT2A receptor antagonists and demonstration of synergistic effects with the hypnotic, zolpidem in rats. Neuropharmacology, 2013, 70, 19-26.	4.1	17
117	Preclinical profile of the mixed 5-HT1A/5-HT2A receptor antagonist S 21357. Pharmacology Biochemistry and Behavior, 1996, 54, 509-516.	2.9	16
118	Awakening properties of newly discovered highly selective H3 receptor antagonists in rats. Behavioural Brain Research, 2012, 232, 416-420.	2.2	16
119	Evidence that tolerance to the anxiogenic-like effects of mCPP does not involve alteration in the function of 5-HT2C receptors in the rat choroid plexus. Behavioural Pharmacology, 1994, 5, 642-646.	1.7	15
120	The neurokinin NK2 antagonist, saredutant, ameliorates stress-induced conditions without impairing cognition. Pharmacology Biochemistry and Behavior, 2011, 98, 405-411.	2.9	14
121	The CRF1 receptor antagonist SSR125543 prevents stress-induced long-lasting sleep disturbances in a mouse model of PTSD: Comparison with paroxetine and d-cycloserine. Behavioural Brain Research, 2015, 279, 41-46.	2.2	12
122	Study of the modulatory activity of bz (Ï‰) receptor ligands on defensive behaviors in mice: Evaluation of the importance of intrinsic efficacy and receptor subtype selectivity. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1999, 23, 81-98.	4.8	11
123	SSR181507, a dopamine D2 receptor and 5-HT1A receptor ligand: Evidence for mixed anxiolytic- and antidepressant-like activities. Pharmacology Biochemistry and Behavior, 2011, 97, 428-435.	2.9	8
124	Neuropeptide Receptor Ligands for the Treatment of Schizophrenia: Focus on Neurotensin and Tachykinins. Current Pharmaceutical Design, 2015, 21, 3807-3812.	1.9	8
125	Creativity in large pharmaceutical research organizations: unleash the hungry drug hunter. British Journal of Pharmacology, 2017, 174, 2152-2153.	5.4	6
126	The Mouse Defense Test Battery: An experimental model of different emotional states.. , 0, , 75-85.		6

#	Article	IF	Citations
127	Effects of intra-hippocampal injections of the NK2 receptor antagonist saredutant on the elevated plus maze, and the mouse defense test battery. Neuroscience Letters, 2010, 485, 241-245.	2.1	5
128	Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleepâ€“wake disorders. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6141-6145.	2.2	5
129	The Mouse Defense Test Battery: A Model Measuring Different Facets of Anxiety-Related Behaviors. Neuromethods, 2011, , 97-106.	0.3	5
130	Chapter 1.1 Introduction to the handbook on fear and anxiety. Handbook of Behavioral Neuroscience, 2008, 17, 3-7.	0.7	4
131	Response to Roesler et al.: Neuropeptides and stress-related disorders â€“ multiple targets and converging concepts. Trends in Pharmacological Sciences, 2004, 25, 242-243.	8.7	3
132	Long-lasting memory abnormalities following exposure to the mouse defense test battery: An animal model of PTSD. Physiology and Behavior, 2015, 146, 67-72.	2.1	3
133	Tachykinins. , 2010, , 1301-1303.		3
134	Prolactin similar to ectopic pituitary isograft restores responsiveness in Snell dwarf mice. NeuroReport, 1992, 3, 210.	1.2	2
135	CRF1 receptor antagonists do not reverse pharmacological disruption of prepulse inhibition in rodents. Psychopharmacology, 2014, 231, 1289-1303.	3.1	2
136	Nonpeptide vasopressin V1b receptor antagonists. Handbook of Behavioral Neuroscience, 2005, 15, 409-421.	0.0	1
137	Editorial [Hot Topic: Neuropeptide Systems as Novel Targets for Psychiatric Disorders (Guest Editor:) Tj ETQq1 1 0.784314 rgBT /Over	1.4	1
138	Chapter 4.6 Genetic factors underlying anxiety-behavior: A meta-analysis of rodent studies involving targeted mutations of neurotransmission genes. Handbook of Behavioral Neuroscience, 2008, 17, 325-354.	0.7	1
139	Pharmacology, Biochemistry and Behavior: The 2015 Transition. Pharmacology Biochemistry and Behavior, 2015, 131, iii.	2.9	1
140	Subtype-selective benzodiazepine receptor ligands. , 2000, , 77-94.		1
141	Tachykinins. , 2014, , 1-4.		0